重症筋無力症(Myasthenia Gravis)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Myasthenia Gravis Overview 8
Therapeutics Development 9
Pipeline Products for Myasthenia Gravis – Overview 9
Pipeline Products for Myasthenia Gravis – Comparative Analysis 10
Myasthenia Gravis – Therapeutics under Development by Companies 11
Myasthenia Gravis – Therapeutics under Investigation by Universities/Institutes 13
Myasthenia Gravis – Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Myasthenia Gravis – Products under Development by Companies 17
Myasthenia Gravis – Products under Investigation by Universities/Institutes 18
Myasthenia Gravis – Companies Involved in Therapeutics Development 19
Alexion Pharmaceuticals, Inc. 19
Alnylam Pharmaceuticals, Inc. 20
Astellas Pharma Inc. 21
Biokine Therapeutics Ltd. 22
CuraVac, Inc. 23
Cytokinetics, Inc. 24
GlaxoSmithKline plc 25
Grifols, S.A. 26
HanAll Biopharma Co., Ltd. 27
Neurotune AG 28
Pfizer Inc. 29
Regenesance BV 30
Toleranzia AB 31
Myasthenia Gravis – Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
ALN-CC5 – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
belimumab – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
BKT-130 – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
CK-2066260 – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
eculizumab – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
GL-2045 – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
HL-161 – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
immune globulin (human) – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
NT-1654 – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Recombinant Protein for Myasthenia Gravis – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Recombinant Protein to Antagonize LTB4 and C5 for Respiratory, Immunological, CNS and Hematological Disorders – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Regenemab – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
tacrolimus – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
tirasemtiv – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Vaccine for Myasthenia Gravis – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Vaccine for Myasthenia Gravis – Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Myasthenia Gravis – Recent Pipeline Updates 69
Myasthenia Gravis – Dormant Projects 85
Myasthenia Gravis – Discontinued Products 86
Myasthenia Gravis – Product Development Milestones 87
Featured News & Press Releases 87
Dec 10, 2014: Soliris (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Myasthenia Gravis 87
Sep 16, 2014: Alnylam Presents New Pre-Clinical Data with ALN-CC5, a Subcutaneously Administered RNAi Therapeutic Targeting Complement Component C5 in Development for the Treatment of Complement-Mediated Diseases 88
Aug 01, 2014: European Commission Grants Orphan Drug Designation to Soliris (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG) 89
Jun 17, 2014: FDA Grants Orphan Drug Designation to Soliris (eculizumab) for the Treatment of Patients with Myasthenia Gravis 90
Jun 09, 2014: Alnylam Presents New Pre-Clinical Data with Development Candidate for ALN-CC5, a Subcutaneously Administered RNAi Therapeutic Targeting Complement Component C5 in Development for the Treatment of Complement-Mediated Diseases 90
Apr 24, 2014: Alexion Initiates Multinational Registration Trials of Eculizumab as a Potential Treatment for Patients with Relapsing Neuromyelitis Optica and Refractory Generalized Myasthenia Gravis 92
Apr 24, 2014: Toleranzia supported by VINNOVA 93
Dec 08, 2013: New Alnylam Pre-clinical Results on ALN-CC5, an RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated Diseases, Demonstrate up to 98% Serum C5 Knockdown and up to 94% Inhibition of Hemolytic Activity in Non-Human Primates 93
Jun 20, 2013: Alnylam Scientists Present Preclinical Data With ALN-CC5 For Treatment Of Complement-mediated Diseases 96
Mar 21, 2013: Cytokinetics Announces Presentation Of Phase IIA Clinical Trial Data Of Tirasemtiv In Patients With Myasthenia Gravis 97
Appendix 99
Methodology 99
Coverage 99
Secondary Research 99
Primary Research 99
Expert Panel Validation 99
Contact Us 100
Disclaimer 100